Skip to main content
SpringerLink
Log in

Bariatric Surgery in Treatment of the Obese Patient with Type 2 Diabetes

  • Chapter
  • First Online:
Book cover Endocrinology and Diabetes

  • 2959 Accesses

Abstract

Rising prevalence of obesity.

Recent publications analyzing contemporary and historical trends in worldwide prevalence of obesity have provided us with some sobering predictions. Currently greater than two-thirds of Americans are considered over-weight (BMI ≥ 25 kg/m2) and over one-third are obese (BMI ≥ 30 kg/m2) (Wang et al., Lancet 378:815–25, 2011). If current trends hold, the number of obese Americans is expected to increase to greater than 50 % by 2030 (Wang et al., Lancet 378:815–25, 2011). The devastating impact of obesity’s rising prevalence is imminent, both in terms of our citizenry’s health and in the financial well-being of our healthcare industry as a whole.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hu FB et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001;345:790–7.

    Article  PubMed  CAS  Google Scholar 

  2. Must A et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523–9.

    Article  PubMed  CAS  Google Scholar 

  3. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007;121:492–6.

    Article  PubMed  CAS  Google Scholar 

  4. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual Deaths Attributable to Obesity in the United States. JAMA. 1999;282:1530–8.

    Article  PubMed  CAS  Google Scholar 

  5. Despres JP, Fong BS, Julien P, Jimenez J, Angel A. Regional variation in HDL metabolism in human fat cells: effect of cell size. Am J Physiol Endocrinol Metab. 1987;252:E654–9.

    CAS  Google Scholar 

  6. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia. 1976;12:563–71.

    Article  PubMed  CAS  Google Scholar 

  7. Campbell PJ, Gerich JE. Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. J Clin Endocrinol Metab. 1990;70:1114–8.

    Article  PubMed  CAS  Google Scholar 

  8. Després J-P et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol. 2008;28: 1039–49.

    Article  PubMed  Google Scholar 

  9. Blackburn GL, Read JL. Benefits of reducing–revisited. Postgrad Med J. 1984;60 Suppl 3:13–8.

    PubMed  Google Scholar 

  10. Prospective UK. Diabetes study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metab Clin Exp. 1990;39:905–12.

    Article  Google Scholar 

  11. Henry RR, Gumbiner B. Benefits and limitations of very-low-calorie diet therapy in obese NIDDM. Diabetes Care. 1991;14:802–23.

    Article  PubMed  CAS  Google Scholar 

  12. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990–8.

    Article  PubMed  CAS  Google Scholar 

  13. Markovic TP et al. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care. 1998;21:695–700.

    Article  PubMed  CAS  Google Scholar 

  14. Sjöström L et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.

    Article  PubMed  Google Scholar 

  15. Tsai AG, Wadden TA. Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med. 2005;142:56–66.

    Article  PubMed  Google Scholar 

  16. Heath V. Obesity: benefits of intensive lifestyle modification programs in the spotlight. Nat Rev Endocrinol. 2011;7:1.

    Article  PubMed  Google Scholar 

  17. Wadden TA, Stunkard AJ, Brownell KD. Very low calorie diets: their efficacy, safety, and future. Ann Intern Med. 1983;99:675–84.

    Article  PubMed  CAS  Google Scholar 

  18. Henry RR, Wiest-Kent TA, Scheaffer L, Kolterman OG, Olefsky JM. Metabolic consequences of very-low-calorie diet therapy in obese non-insulin-dependent diabetic and nondiabetic subjects. Diabetes. 1986;35:155–64.

    Article  PubMed  CAS  Google Scholar 

  19. Amatruda JM, Biddle TL, Patton ML, Lockwood DH. Vigorous supplementation of a hypocaloric diet prevents cardiac arrhythmias and mineral depletion. Am J Med. 1983;74:1016–22.

    Article  PubMed  CAS  Google Scholar 

  20. Henry RR, Scheaffer L, Olefsky JM. Glycemic effects of intensive caloric restriction and isocaloric refeeding in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1985;61:917–25.

    Article  PubMed  CAS  Google Scholar 

  21. Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11:361–71.

    Article  PubMed  CAS  Google Scholar 

  22. Lloret-Linares C, Greenfield JR, Czernichow S. Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. Diabet Med. 2008;25:1142–50.

    Article  PubMed  CAS  Google Scholar 

  23. Johansson K, Sundström J, Neovius K, Rössner S, Neovius M. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis. Obes Rev. 2010;11:777–91.

    Article  PubMed  CAS  Google Scholar 

  24. O’Neil PM et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.

    Article  PubMed  Google Scholar 

  25. Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377: 1341–52.

    Article  PubMed  CAS  Google Scholar 

  26. Garvey WT et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297–308.

    Article  PubMed  CAS  Google Scholar 

  27. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery. 2007;142:621–35.

    Article  PubMed  Google Scholar 

  28. Gagner M et al. Laparoscopic sleeve gastrectomy for the super-super-obese (body mass index >60 kg/m(2)). Surg Today. 2008;38:399–403.

    Article  PubMed  Google Scholar 

  29. Buchwald H et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–256.e5.

    Article  PubMed  Google Scholar 

  30. Pories WJ et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:339–50. discussion 350–352.

    Article  PubMed  CAS  Google Scholar 

  31. Buchwald H et al. Bariatric surgery. JAMA. 2004;292:1724–37.

    Article  PubMed  CAS  Google Scholar 

  32. Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis. 2009;5:469–75.

    Article  PubMed  Google Scholar 

  33. Kellum JM et al. Gastrointestinal hormone responses to meals before and after gastric bypass and vertical banded gastroplasty. Ann Surg. 1990;211:763–70. discussion 770–771.

    Article  PubMed  CAS  Google Scholar 

  34. Perugini RA, Malkani S. Remission of type 2 diabetes mellitus following bariatric surgery: review of mechanisms and presentation of the concept of ‘reversibility’. Curr Opin Endocrinol Diabetes Obes. 2011;18: 119–28.

    Article  PubMed  Google Scholar 

  35. Morínigo R et al. Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2006;91:1735–40.

    Article  PubMed  Google Scholar 

  36. Clements RH, Gonzalez QH, Long CI, Wittert G, Laws HL. Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg. 2004;70:1–4. discussion 4–5.

    PubMed  Google Scholar 

  37. Laferrère B et al. Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care. 2007;30:1709–16.

    Article  PubMed  Google Scholar 

  38. Laferrère B et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.

    Article  PubMed  Google Scholar 

  39. Batterham RL et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med. 2003;349: 941–8.

    Article  PubMed  CAS  Google Scholar 

  40. Carr RD et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab. 2010;95:872–8.

    Article  PubMed  CAS  Google Scholar 

  41. Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365: 1597–604.

    Article  PubMed  CAS  Google Scholar 

  42. Cummings DE et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002;346:1623–30.

    Article  PubMed  Google Scholar 

  43. Engstrom BE, Ohrvall M, Sundbom M, Lind L, Karlsson FA. Meal suppression of circulating ghrelin is normalized in obese individuals following gastric bypass surgery. Int J Obes. 2006;31:476–80.

    Article  Google Scholar 

  44. Morínigo R et al. Short-term effects of gastric bypass surgery on circulating ghrelin levels. Obes Res. 2004;12:1108–16.

    Article  PubMed  Google Scholar 

  45. Evans S et al. Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction. Surg Endosc. 2012;26: 1086–94.

    Article  PubMed  Google Scholar 

  46. Peterli R et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22:740–8.

    Article  PubMed  Google Scholar 

  47. Melissas J et al. Sleeve gastrectomy—a ‘food limiting’ operation. Obes Surg. 2008;18:1251–6.

    Article  PubMed  Google Scholar 

  48. Aguirre V, Stylopoulos N, Grinbaum R, Kaplan LM. An endoluminal sleeve induces substantial weight loss and normalizes glucose homeostasis in rats with diet-induced obesity. Obesity (Silver Spring). 2008; 16:2585–92.

    Article  CAS  Google Scholar 

  49. Franz MJ et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc. 2007;107:1755–67.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN, 55905, USA

    Manpreet S. Mundi M.D. & Maria Collazo-Clavell M.D.

Authors
  1. Manpreet S. Mundi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Collazo-Clavell M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Manpreet S. Mundi M.D. .

Editor information

Editors and Affiliations

  1. Professor Associado e Livre-Docente, Disciplina de Endocrinologia da Faculdade de Ciências Medicas da Universidade de Pernambuco, Chefe da Divisão de Endocrinologia e Diabetes do Hospital Agamenon, Magalhães-MS/UPE, Recife, Brazil

    Francisco Bandeira

  2. American Thyroid Association Past President, American Association of Clinical Endocrinologists, Professor of Medicine, Mayo Clinic College of Medicine President-Elect, Rochester, Minnesota, USA

    Hossein Gharib

  3. Federal Foundation and School of Medical Sciences, Porto Alegre, Brazil

    Airton Golbert

  4. Department of Medicine, University of Pernambuco School of Medicine, Recife, Brazil

    Luiz Griz

  5. Department of Medicine, University of Maranhao School of Medicine, Sao Luis, Brazil

    Manuel Faria

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Mundi, M.S., Collazo-Clavell, M. (2014). Bariatric Surgery in Treatment of the Obese Patient with Type 2 Diabetes. In: Bandeira, F., Gharib, H., Golbert, A., Griz, L., Faria, M. (eds) Endocrinology and Diabetes. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8684-8_42

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8684-8_42

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8683-1

  • Online ISBN: 978-1-4614-8684-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation